Research programme: cardiovascular therapeutics - Bio3 Research

Drug Profile

Research programme: cardiovascular therapeutics - Bio3 Research

Alternative Names: CT 301/R; CT 406; Mimic-Abs HMGB1-specific; siRNA HMGB1 specific

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bio3 Research
  • Class Monoclonal antibodies
  • Mechanism of Action Protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cardiovascular disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cardiovascular-disorders in Italy (Parenteral)
  • 19 Jul 2010 Preclinical development is ongoing in Italy
  • 12 Feb 2007 Preclinical trials in Cardiovascular disorders in Italy (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top